Table 2.
Association of SChLAP1 Expression with Clinicopathologic Parameters in a Cohort of Patients with Clinically Localized Prostate Cancer Treated by Radical Prostatectomy.
| SChLAP1 ISH Score < 100 (n = 127) | SChLAP1 ISH Score ≥ 100 (n = 33) | P Value | |
|---|---|---|---|
| Age, y | |||
| ≤ 60 | 68 (53.5%) | 18 (54.5%) | 1.000 |
| > 60 | 59 (46.5%) | 15 (45.5%) | |
| Race | |||
| Black | 14 (11.0%) | 4 (12.1%) | .294 |
| White | 104 (81.9%) | 24 (72.7%) | |
| Other/unknown | 9 (7.1%) | 5 (15.2%) | |
| Preoperative PSA, ng/ml | |||
| ≤ 7 | 70 (55.1%) | 20 (60.6%) | .694 |
| > 7 | 57 (44.9%) | 13 (39.4%) | |
| DRE | |||
| T1 | 87 (68.5%) | 18 (54.5%) | .152 |
| T2 | 40 (31.5%) | 15 (45.5%) | |
| Gland weight, g | |||
| ≤ 50 | 79 (62.2%) | 27 (81.8%) | .039 |
| > 50 | 48 (37.8%) | 6 (18.2%) | |
| Tumor size, cm | |||
| ≤ 1.5 | 69 (54.3%) | 17 (51.5%) | .846 |
| > 1.5 | 58 (45.7%) | 16 (48.5%) | |
| Multifocal | |||
| No | 29 (22.8%) | 8 (26.7%) | .639 |
| Yes | 98 (77.2%) | 22 (73.3%) | |
| GS | |||
| < 7 | 37 (29.1%) | 4 (12.1%) | .017 |
| = 7 | 85 (66.9%) | 24 (72.7%) | |
| > 7 | 5 (3.9%) | 5 (15.2%) | |
| Surgical margin | |||
| Negative | 92 (72.4%) | 22 (66.7%) | .523 |
| Positive | 35 (27.5%) | 11 (33.3%) | |
| EPE | |||
| Negative | 102 (80.3%) | 21 (63.6%) | .063 |
| Positive | 25 (19.7%) | 12 (36.4%) | |
| SVI | |||
| Negative | 125 (98.4%) | 28 (84.8%) | .004 |
| Positive | 2 (1.6%) | 5 (15.2%) | |
| AJCC N stage | |||
| pNX or pN0 | 115 (90.6%) | 27 (90.0%) | 1.000 |
| pN1 | 12 (9.4%) | 3 (10.0%) | |
| PSA recurrence | |||
| Negative | 92 (72.4%) | 17 (51.5%) | .035 |
| Positive | 35 (27.6%) | 16 (48.5%) | |
| Path1992 | |||
| ≤ 3 | 102 (80.3%) | 20 (60.6%) | .023 |
| > 3 | 25 (19.7%) | 13 (30.4%) | |
| Path1997 | |||
| < 3 | 102 (80.3%) | 20 (60.6%) | .023 |
| ≥ 3 | 25 (19.7%) | 13 (39.4%) |
DRE, digital rectal examination; EPE, extraprostatic extension; SVI, seminal vesicle invasion.
Note: There were 3 patients missing AJCC N stage and multifocal records; hence, we used 157 patients for testing AJCC N stage and multifocal, but 160 patients for other parameters.